Results 101 to 110 of about 20,100 (304)

First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis. [PDF]

, 2014
BackgroundAtypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized ...
A Szilagyi, Aspazija Sofijanova, Attila Szabó, C Loirat, CM Legendre, D Kavanagh, D Magen, F Fakhouri, F Fakhouri, G Ariceta, G Ariceta, György Reusz, J Caprioli, J Zuber, J Zuber, JM Campistol, Klaus Arbeiter, Krisztina Rusai, Lilla Szeifert, LM Geerdink, M Christmann, M Heurich, M Jozsi, M Lemaire, M Reti, MA Abrera-Abeleda, MA Dragon-Durey, Miklós Szabó, N Besbas, Nóra Szarvas, RA Gruppo, RL Ruebner, S Jung, Thomas Müller, Valbona Nushi-Stavileci, Velibor Tasic, Z Prohaszka, Zoltán Prohászka, Zoran Gucev, Ágnes Szilágyi   +39 more
core   +1 more source

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 895-908, July 2025.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study

Frontiers in Pharmacology, 2020
To date, there are no specific therapeutic strategies for treatment of COVID-19. Based on the hypothesis that complement and coagulation cascades are activated by viral infection, and might trigger an acute respiratory distress syndrome (ARDS), we report
V. Giudice, P. Pagliano, A. Vatrella, A. Masullo, S. Poto, B. Polverino, Renato Gammaldi, A. Maglio, C. Sellitto, C. Vitale, B. Serio, B. Cuffa, A. Borrelli, C. Vecchione, A. Filippelli, C. Selleri   +15 more
semanticscholar   +1 more source

Eculizumab in Pediatric Dense Deposit Disease [PDF]

Clinical Journal of the American Society of Nephrology, 2015
Dense deposit disease (DDD), a subtype of C3 glomerulopathy, is a rare disease affecting mostly children. Treatment options are limited. Debate exists whether eculizumab, a monoclonal antibody against complement factor C5, is effective in DDD. Reported data are scarce, especially in children.The authors analyzed clinical and histologic data of five ...
Oosterveld, M.J.S., Garrelfs, M.R., Hoppe, B., Florquin, S., Roelofs, J.J., van den Heuvel, B., van den Heuvel, B., Amann, K., Davin, J.C., Bouts, A.H., Schriemer, P.J., Groothoff, J.W.   +11 more
openaire   +4 more sources

Eculizumab for Shiga‐toxin‐induced hemolytic uremic syndrome in adults with neurological involvement

eJHaem
The role of eculizumab in treating Shiga‐toxin‐producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) patients with neurological involvement remains unclear.
Benjamin J. Lee, Zhaohui Arter, Jean Doh, Shawn P. Griffin, Pongthep Vittayawacharin, Steven Atallah, Kevin R. Shieh, Minh‐Ha Tran, Sonata Jodele, Piyanuch Kongtim, Stefan O. Ciurea   +10 more
doaj   +1 more source

Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017). [PDF]

, 2019
BACKGROUND: To describe patients with inherited and acquired complement deficiency who developed invasive meningococcal disease (IMD) in England over the last decade. METHODS: Public Health England conducts enhanced surveillance of IMD in England.
Bai, X, Borrow, R, Campbell, H, Clark, SA, Gray, S, Ladhani, SN, Lekshmi, A, Lucidarme, J, Parikh, S, Patel, S, Ramsay, M, Walker, A, Willerton, L   +12 more
core   +1 more source

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial

Clinical and Translational Science, Volume 18, Issue 7, July 2025.
ABSTRACT HSK39297 is a novel complement factor B inhibitor, and this phase 1 trial was designed to assess its pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability in healthy Chinese subjects. This study included 46 subjects in the single ascending dose (SAD) part (50–600 mg) and 50 subjects in the multiple ascending dose (MAD) part ...
Yuyang Dai, Feng Wu, Siyang Ni, Xiaojun Hu, Ying Han, Ying Jiao, Huan Lu, Yilin Liu, Lingling Wang, Yunfei Lin, Meixia Chen, Chao Wang, Qinghe Wu, Fangqiong Li, Laichun Lu   +14 more
wiley   +1 more source

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab

Blood, 2021
Some patients with paroxysmal nocturnal hemoglobinuria (PNH) remain persistently anemic despite treatment with eculizumab and may have significant extravascular hemolysis.
Austin Kulesekararaj, A. Risitano, J. Maciejewski, R. Notaro, P. Browett, J. W. Lee, Mingjun Huang, M. Geffner, R. Brodsky   +8 more
semanticscholar   +1 more source

Eculizumab in secondary atypical haemolytic uraemic syndrome [PDF]

Nephrology Dialysis Transplantation, 2017
Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres ...
Cavero, Teresa, Rabasco, Cristina, López, Antía, Román, Elena, Ávila, Ana, Sevillano, Ángel, Huerta, Ana, Rojas-Rivera, Jorge, Fuentes, Carolina, Blasco, Miquel, Jarque, Ana, García, Alba, Mendizabal, Santiago, Gavela, Eva, Macía, Manuel, Quintana, Luis F., Romera, Ana María, Borrego, Josefa, Arjona, Emi, Espinosa, Mario, Portolés Pérez, José María, Gracia Iguacel, Carolina Marta, González Parra, Emilio José, Aljama, Pedro, Morales, Enrique, Cao, Mercedes, Rodríguez de Córdoba, Santiago, Praga, Manuel   +27 more
openaire   +9 more sources

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. [PDF]

, 2014
Neuromyelitis optica (NMO) is an autoimmune disease of the CNS that is characterized by inflammatory demyelinating lesions in the spinal cord and optic nerve, potentially leading to paralysis and blindness.
A Bar-Or, A Davies, A Iyer, A Jacob, A Jacob, A Jacob, A Jacob, A McKeon, A Nagaishi, A Rossi, A Uzawa, A Warth, AE Damiano, Alan S. Verkman, AMC Faria, B Banwell, B Bielekova, B Bourre, B Weinstock-Guttman, BA Cree, BC Kieseier, BG Weinshenker, BL Raveendra, BM Greenberg, BM Greenberg, C Costanzi, C Trebst, C Wrzos, CF Lucchinetti, CH Polman, D Ricklin, D Ricklin, D Yuksel, DB Bichuetti, DB Bichuetti, DG Brum, DJ Kimbrough, DK Sato, DM Wingerchuk, DM Wingerchuk, E Gomori, EW Gelfand, F Shimizu, G Pentón-Rol, GG Illei, GS Bedi, H Kita, H Merle, H Wang, H Wen, H Yaguchi, H Zephir, H Zhang, H Zhang, HH Wang, HL Pellkofer, HL Pellkofer, HL Pellkofer, HM Reeves, I Ayzenberg, I Kleiter, I Kleiter, I Nakashima, J Bakker, J Fagius, J Kitley, J Kitley, J Kitley, J Kitley, J Kitley, J Kitley, J Palace, J Ratelade, J Ratelade, J Ratelade, J Ratelade, J Shimizu, JA Cabrera-Gomez, Jeffrey L. Bennett, JH Min, JL Bennett, JM Crane, JM Tillema, JR Faulkner, JS Wu, K Iwata, K Kawabata, K Miyamoto, K Okada, K Rostasy, K Sugita, KR Carson, L Elsone, L Tradtrantip, L Tradtrantip, L Tradtrantip, L Tradtrantip, LA Lewis, M Araki, M Barnett, M Bonnan, M Bonnan, M Botto, M Bradl, M Collin, M De Falco, M Keegan, M Koga, M Matiello, M Matiello, M Pohl, M Reindl, M Ringelstein, M Varrin-Doyer, MA Mealy, MA Sahraian, Marios C. Papadopoulos, MC Papadopoulos, MJ Magraner, N Asavapanumas, N Asavapanumas, N Asgari, N Chihara, N Chihara, N Muls, O Hammer, P Cabre, P Huppke, P Imbach, PF Zipfel, PJ Barnes, PW Phuan, PW Phuan, PW Phuan, R Deschamps, R Reuss, RC Axtell, RE Young, RR Voskuhl, S Izaki, S Jacob, S Jarius, S Jarius, S Jarius, S Jarius, S Jarius, S Jarius, S Jarius, S Kim, S Mader, S Mihai, S Saadoun, S Saadoun, S Saadoun, S Saadoun, S Saadoun, S Saadoun, S Watanabe, S-H Kim, S-H Kim, S-H Kim, S-H Kim, SH Kim, SJ Pittock, SR Hinson, SR Hinson, SR Hinson, SR Kalluri, T Hosokawa, T Kageyama, T Matsuoka, T Matsushita, T Vincent, TE Lotze, TF Tedder, UC Linhares, V Papayannopoulos, VA Lennon, VA Lennon, VT Chu, W Kim, Y Li, Y Warabi, YD Fragoso   +183 more
core   +1 more source